Boston Scientific (NYSE:BSX) sought to dispel concerns that its thinner next-generation stents may be more prone to crumpling than some other models with the release of results from 2 randomized clinical trials which found no instances of deformation with the med-tech titan’s newest stents.
Abbott
Stent Wars: DES best bare metal stents
Updated March 26, 2012 at 9:23 a.m. with new details on Promus/Xience private label deal and March 23, 2012 at 1:15 p.m. with comments from Medtronic.
Analyst: CRM market “bad as it’s ever been” | Wall Street Beat
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.
IBM’s Watson supercomputer tackles cancer | MassDevice.com On Call
MASSDEVICE ON CALL — IBM’s Jeopardy-winning Watson supercomputer is taking a swing at oncology research in efforts to help hospitals more quickly diagnose and treat cancer.
Watson can cull through 200 million pages of information in less than 3 seconds, according to IBM, and the machine is getting an education in oncology at Manhattan’s Memorial Sloan-Kettering Cancer Center.
FDA wrestles with mobile medical apps and self-screening devices | MassDevice.com On Call
MASSDEVICE ON CALL — The FDA will meet this month to consider the role the agency will play in mobile medical technologies and patient-driven screening and diagnostics.
The agency forecasts that patients will soon have access to technologies that allow them to self-screen for diseases or conditions via stand-alone kiosks or wireless diagnostic tools like blood pressure readers and blood glucose readers.
Abbott brass takes pay cuts | Personnel Moves
VCs press Senate on “IPO On Ramp” bill | Wall Street Beat
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
MassDevice.com +3 | The top 3 med-tech stories for March 9, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Diabetes: Abbott lands FDA win for touch-screen glucose monitor | Regulatory Roundup
Medtronic settles off-label biliary stent lawsuit | Legal News
U.S. Attorney’s office for Massachusetts dropped a years-long inquiry into allegations that Medtronic (NYSE:MDT) promoted off-label use for its biliary stents.
The Bay State feds told Medtronic Feb. 9 that the 3-year-old investigation is no longer active, according to a regulatory filing.
The probe began in June 2008, when the Fridley, Minn.-based med-tech company received a subpoena from the U.S. attorney’s office for doucments and data related to possible off-label marketing of the stents.
Piper Jaffray: Abiomed wins reimbursement code | Wall Street Beat
Abiomed (NSDQ:ABMD) is slated to win a reimbursement code for procedures involving its Impella heart pump, according to analysts at Piper Jaffray.
In a summary of recent editorial panel decisions, the American Medical Assn. revealed that the panel approved the Society for Cardiovascular Angiography and Interventions’ proposal for the reimbursement code, according to theflyonthewall.com.